Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Mixed Lineage Leukemia”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Early research (Phase 1)Study completedNCT01684150
What this trial is testing

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome+1 more
Epizyme, Inc. 51
Testing effectiveness (Phase 2)Looking for participantsNCT04065399
What this trial is testing

Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Lineage Acute Leukemia+2 more
Syndax Pharmaceuticals 447
Testing effectiveness (Phase 2)Looking for participantsNCT04988555
What this trial is testing

DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Sumitomo Pharma America, Inc. 362
Testing effectiveness (Phase 2)Study completedNCT02799147
What this trial is testing

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Who this might be right for
Leukemia, Acute LymphoblasticAcute Myeloid LeukemiaMixed-Lineage Acute Leukemias
St. Petersburg State Pavlov Medical University 27
Early research (Phase 1)Active Not RecruitingNCT01815749
What this trial is testing

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Who this might be right for
Adult Grade III Lymphomatoid GranulomatosisCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue+21 more
City of Hope Medical Center
Early research (Phase 1)Looking for participantsNCT04375631
What this trial is testing

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+6 more
Fred Hutchinson Cancer Center 120
Testing effectiveness (Phase 2)Ended earlyNCT00866281
What this trial is testing

The Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05761171
What this trial is testing

Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Who this might be right for
Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage+9 more
Children's Oncology Group 78
Testing effectiveness (Phase 2)Ended earlyNCT02419755
What this trial is testing

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Who this might be right for
Mixed Lineage Acute LeukemiaAcute Myeloid LeukemiaAcute Lymphoid Leukemia
St. Jude Children's Research Hospital 12
Early research (Phase 1)Looking for participantsNCT03826992
What this trial is testing

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Who this might be right for
Leukemia
Children's Hospital Medical Center, Cincinnati 21
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Early research (Phase 1)Study completedNCT01925131
What this trial is testing

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Acute Leukemias of Ambiguous LineageB-cell Adult Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia+2 more
SWOG Cancer Research Network 50
Testing effectiveness (Phase 2)Looking for participantsNCT04067336
What this trial is testing

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Advanced Malignant NeoplasmAcute Myeloid LeukemiaMixed Lineage Leukemia+4 more
Kura Oncology, Inc. 263
Early research (Phase 1)Study completedNCT00889408
What this trial is testing

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Who this might be right for
LeukemiaLymphoma
Masonic Cancer Center, University of Minnesota 25
Early research (Phase 1)Active Not RecruitingNCT02091245
What this trial is testing

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Who this might be right for
Relapsed Acute Lymphoblastic Leukemia (ALL)Refractory Acute Lymphoblastic Leukemia (ALL)Relapsed Acute Myelogenous Leukemia (AML)+6 more
Dana-Farber Cancer Institute 16
30